Embedded Files
A UnitedHealthcare plan administered by Optum Rx left a psoriatic arthritis patient owing $441 for month two of Otezla after his $9,450 Amgen copay card was rapidly depleted — prompting him to ration doses and see symptoms return. The case spotlights how copay assistance can fail when PBM “negotiated” pricing isn’t applied and coupon dollars don’t count toward deductibles or out-of-pocket maximums.
The Move
A patient with psoriatic arthritis improved on Otezla (apremilast) after starting Amgen’s copay assistance, expecting near-$0 out-of-pocket costs for a year.
His UnitedHealthcare pharmacy benefit (via Optum Rx) processed the fill such that the manufacturer coupon was “used outside of insurance,” didn’t apply to deductible/OOP max, and appeared not to apply a negotiated discount on the claim.
Result: a $5,253.85 30-day charge, insurer paid $308.34, and the copay card was exhausted quickly—leaving a $441.02 bill by month two and later warnings he could owe thousands to hit his OOP max.
Why it Matters for Care
Adherence risk is immediate: the patient rationed (skipped days/half-dosed) to stretch supply, and symptoms returned—an avoidable flare tied to benefit design, not clinical decision-making.
Clinicians may inadvertently overpromise affordability when patients present with copay cards; “$0” marketing can collapse once accumulator/maximizer policies and claim routing kick in.
At the bedside, the practical question becomes: can the patient sustain the therapy past the first fill? For Otezla, list price is ~ $5,000/month; even brief gaps can undermine disease control and function (e.g., hand pain affecting work).
Between the Lines
Copay cards are a market lever: they steer patients toward brand drugs (sometimes non-preferred) and away from lower-cost alternatives, while insurers/PBMs respond with restrictions that shift cost back to patients.
Accumulator policies (coupon dollars not counting toward deductible/OOP max) can preserve plan savings but create mid-year “sticker shock” and destabilize chronic disease management.
Manufacturers blame plans for forcing patients to “pay the full list price”; plans frame coupons as separate from insurance—leaving patients caught between two pricing narratives.
Patent and litigation strategy matters clinically: although FDA approved a generic Otezla in 2021, Amgen lawsuits have helped keep U.S. generics off the market until 2028, sustaining high prices and the reliance on assistance programs.
What to Watch
State and federal scrutiny of PBM practices (including transparency around negotiated prices and coupon accumulator policies) that could reshape how coupons are applied at the point of sale.
Employer and insurer benefit design changes for 2026 (e.g., plans that cover a drug at a flat copay vs high deductibles) and how clearly those options are communicated to patients.
Otezla patent/litigation timelines through 2028 and whether earlier generic entry changes formulary placement, patient cost-sharing, and adherence patterns.
More “Bill of the Month”-style cases that drive legislative hearings—especially as patients report rationing specialty and chronic meds due to benefit mechanics rather than clinical choice.
Source: KFF Health News
Page updated
Report abuse